{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:40:20Z","timestamp":1786653620127,"version":"build-2736575974"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Erythrodermic psoriasis (EP) is a rare but severe form of psoriasis. Conventional treatments are often ineffective and challenging to maintain; however, new biologic medications have shown promise in the management of EP with limited evidence. To assess the efficacy and safety of two biological treatments, adalimumab and secukinumab, in patients with EP. This single centre study was performed from 8 August 2019 to 12 June 2023. Patients demonstrating psoriasis involving over 75% of body surface area were included. The psoriasis area severity index (PASI) score was recorded during follow-up. A total of 20 patients fulfilling the diagnostic criteria for EP were enrolled in the study. At week 24, 50% improvement of PASI (PASI50), PASI75, PASI90 and PASI100 was reached in 95%, 65%, 45% and 15% of patients, respectively. Adalimumab and secukinumab elicited similar PASI responses. The percentages of PASI responders with comorbidities were lower than that of their counterparts in general. Minor adverse events occurred in 30% of patients, and none was forced to suspend the corresponding drug. A remarkable efficacy was demonstrated by adalimumab and secukinumab in treating EP, with rapid and substantial clinical improvement observed in the majority of patients. Both had a well-tolerated safety profile. However, secukinumab seemingly manifested superior response rates than adalimumab in patients with comorbidities.<\/jats:p>","DOI":"10.4103\/ijd.ijd_1051_23","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T05:12:51Z","timestamp":1743138771000},"page":"221-221","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Adalimumab and Secukinumab in Erythrodermic Psoriasis: A Single Centre Retrospective Study"],"prefix":"10.4103","volume":"70","author":[{"given":"Yachen","family":"Wang","sequence":"first","affiliation":[{"name":"From the Department of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishna","family":"Malla","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tianjin Medical University General Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengling","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tianjin Medical University General Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanjing","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tianjin Medical University General Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suju","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tianjin Medical University General Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"R1-20250702","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jaad.2009.05.048","article-title":"Treatment of erythrodermic psoriasis: From the medical board of the National Psoriasis Foundation","volume":"62","author":"Rosenbach","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"R2-20250702","first-page":"841","article-title":"Erythrodermic psoriasis: Epidemiological clinical and therapeutic features about 60 cases","volume":"89","author":"Hawilo","year":"2011","journal-title":"Tunis Med"},{"key":"R3-20250702","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0190-9622(89)70287-5","article-title":"Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients","volume":"21","author":"Boyd","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"R4-20250702","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1087-0024.2004.00831.x","article-title":"Novel immunotherapies for psoriasis: Clinical research delivers new hope for patients and scientific advances","volume":"9","author":"Gottlieb","year":"2004","journal-title":"J Investig Dermatol Symp Proc"},{"key":"R5-20250702","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1365-2133.2012.10940.x","article-title":"Efficacy and safety of biologics in erythrodermic psoriasis: A multicentre, retrospective study: Biologics in erythro- dermic psoriasis","volume":"167","author":"Viguier","year":"2012","journal-title":"Br J Dermatol"},{"key":"R6-20250702","first-page":"241","article-title":"Molecular differences in anticytokine therapies","volume":"21","author":"Calabrese","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"R7-20250702","first-page":"4","article-title":"TNF-alpha inhibitors in dermatology","volume":"12","author":"Cordoro","year":"2007","journal-title":"Skin Ther Lett"},{"key":"R8-20250702","first-page":"779","article-title":"Adalimumab in chronic plaque psoriasis: A clinical guide","volume":"16","author":"Wu","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"R9-20250702","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/S0140-6736(03)12954-6","article-title":"Psoriasis","volume":"361","author":"Lebwohl","year":"2003","journal-title":"Lancet"},{"key":"R10-20250702","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s40265-020-01283-2","article-title":"Targeted treatment for erythrodermic psoriasis: Rationale and recent advances","volume":"80","author":"Shao","year":"2020","journal-title":"Drugs"},{"key":"R11-20250702","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1080\/14712598.2022.2128669","article-title":"Biological treatment for erythrodermic psoriasis","volume":"22","author":"Sunil","year":"2022","journal-title":"Exp Opin Biol Ther"},{"issue":"(Suppl 1)","key":"R12-20250702","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1111\/j.1529-8019.2009.01266.x","article-title":"Treatment of erythrodermic psoriasis in HCV+patient with adalimumab","volume":"22","author":"Richetta","year":"2009","journal-title":"Dermatol Ther"},{"key":"R13-20250702","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/qjmed\/hct139","article-title":"Erythrodermic psoriasis","volume":"107","author":"Mumoli","year":"2014","journal-title":"QJM"},{"key":"R14-20250702","doi-asserted-by":"crossref","first-page":"e12607","DOI":"10.1111\/dth.12607","article-title":"Erythrodermic psoriasis and secukinumab: Our clinical experience","volume":"31","author":"Mateu-Puchades","year":"2018","journal-title":"Dermatol Ther"},{"key":"R15-20250702","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/bjd.16252","article-title":"Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: A case series","volume":"178","author":"Weng","year":"2018","journal-title":"Br J Dermatol"},{"key":"R16-20250702","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/bjd.14013","article-title":"Systemic inflammation and proinflammatory interleukin-17 signalling persist at the end of therapy in patients with metabolic syndrome and psoriasis, reducing the length of remission","volume":"174","author":"Coimbra","year":"2016","journal-title":"Br J Dermatol"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_1051_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:40:07Z","timestamp":1786650007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_1051_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_1051_23","relation":{},"ISSN":["0019-5154","1998-3611"],"issn-type":[{"value":"0019-5154","type":"print"},{"value":"1998-3611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"assertion":[{"value":"2023-11-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}